Barclays PLC Has $882,000 Stake in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Barclays PLC raised its holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) by 70.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 155,179 shares of the biotechnology company's stock after acquiring an additional 64,101 shares during the quarter. Barclays PLC owned about 0.18% of Anavex Life Sciences worth $882,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of AVXL. Orion Capital Management LLC lifted its stake in shares of Anavex Life Sciences by 666.7% in the 3rd quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company's stock valued at $65,000 after purchasing an additional 10,000 shares during the period. Atria Investments Inc acquired a new position in Anavex Life Sciences in the third quarter valued at about $76,000. BNP Paribas Financial Markets boosted its holdings in Anavex Life Sciences by 97.0% during the third quarter. BNP Paribas Financial Markets now owns 15,074 shares of the biotechnology company's stock worth $86,000 after buying an additional 7,421 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Anavex Life Sciences by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 16,309 shares of the biotechnology company's stock worth $93,000 after buying an additional 6,366 shares during the last quarter. Finally, Erste Asset Management GmbH acquired a new position in shares of Anavex Life Sciences during the 3rd quarter worth about $102,000. Institutional investors and hedge funds own 31.55% of the company's stock.

Anavex Life Sciences Trading Down 0.8 %

NASDAQ:AVXL opened at $10.47 on Wednesday. Anavex Life Sciences Corp. has a 1 year low of $3.25 and a 1 year high of $14.44. The stock has a 50-day moving average price of $9.55 and a two-hundred day moving average price of $7.06. The stock has a market cap of $888.02 million, a price-to-earnings ratio of -20.94 and a beta of 0.70.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last issued its quarterly earnings data on Monday, December 23rd. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.03. Sell-side analysts forecast that Anavex Life Sciences Corp. will post -0.55 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. D. Boral Capital reiterated a "buy" rating and issued a $46.00 price target on shares of Anavex Life Sciences in a research report on Monday. HC Wainwright increased their target price on shares of Anavex Life Sciences from $40.00 to $42.00 and gave the stock a "buy" rating in a report on Thursday, December 26th.

Anavex Life Sciences Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.